Business Report: The Case of Cochlear Limited

Executive Overview

Executive summary

Cochlear Limited stands as a globally renowned leader in hearing solutions, particularly in cochlear implants. Annually, the company improves the quality of life for over 40,000 individuals with its scientifically validated hearing implants and products.

Despite its strong market position, the company encountered two major challenges: (i) A lack of deeper emotional connections with its brand and (ii) A limited presence in the senior adult market. To address these, this report recommends a refreshed brand identity, featuring long-term customer stories to build a relatable and inspiring brand image. Additionally, Cochlear should consider expanding its product portfolio to target underserved market segments, particularly the senior market, which holds significant growth potential.

The report provides an analysis of Cochlear’s strategic positioning, performance metrics and competitive landscape. It reveals how the company’s strengths in innovation, customer care and extensive global network – supported by dedicated services for patients and healthcare professionals – have solidified its market leadership. To further build on this foundation, the report proposes actionable strategies to deepen brand engagement and broaden market reach, enhancing Cochlear’s competitive edge and ensuring sustainable growth in a rapidly evolving market.

Introduction

Cochlear is a pioneer and market leader in implantable hearing solutions. However, as the market evolves, the company must adapt to sustain its competitive edge and drive sustainable growth. This report provides a comprehensive analysis of Cochlear Limited’s organizational performance, exploring its strategic objectives, competitive positioning, and market challenges. The objectives of this report are threefold:

1. To examine Cochlear’s current strategy and operational model, including its mission, vision, and strategic capabilities.

2. To evaluate the organization’s competitive strategy by conducting a detailed analysis of its market position, benchmarking performance, and assessing alignment with strategic goals.

3. To provide targeted recommendations for enhancing Cochlear’s future performance, including strategies for growth, brand development, and improving customer experience in untapped markets.

Strategic Analysis

About Cochlear

Cochlear Limited has been a global leader in implantable hearing solutions for over 40 years. Established in 1981 as part of the Nucleus Group, Cochlear became an independent entity and was listed on the Australian Securities Exchange in 1995. Today, the company is valued at over AUD 19 billion, making it one of Australia’s top 50 listed companies. With its headquarters in Sydney, the company operates in more than 180 countries and has a workforce of over 5,000 employees.

Mission and vision

Cochlear’s mission and vision can be summarised into the following statements:

• To make cochlear implants the standard of care for individuals with severe to profound hearing loss.

• To provide bone conduction implants for those with conductive hearing loss, mixed hearing loss, or single-sided deafness.

• To transform the way people understand and treat hearing loss; connect with others and live a full life.

As of 2024, the company has provided more than 750,000 implant devices globally. It continues to innovate, offering new products and upgrades for sound processors to recipients, regardless of when they received their implants.

Macro-environment analysis

For the medical devices industry – hearing solutions segment, an initial list of environmental influences on Cochlear organisation can be summarised under the six PESTLE analysis categories as follows:

From the PESTLE analysis, several uncertain drivers of change emerge that could significantly influence the success or failure of Cochlear’s strategy. These include:

• Regulatory compliance: Meeting local and international medical device regulations and addressing evolving standards.

• Product innovation and development: Staying at the forefront of technological advancements, particularly in cochlear implants.

• Intellectual property (IP) protection: Protecting innovations through patents and managing potential IP disputes.

• Referral network and partnerships: Building and maintaining strong, reliable referral networks with healthcare providers to ensure consistent patient referrals.

Industry structure analysis

Cochlear Limited operates within the medical device industry, specifically in the hearing implant sector. It presents significant opportunities, especially for companies that can innovate, navigate regulatory challenges, and maintain high standards of quality and safety. Here’s how Porter’s five forces framework can be applied to analyse the attractiveness (profit potential) of the industry:

Threat of New Entrants – Low

• (High) entry barriers due to strict regulatory requirements, significant capital investment (plants, R&D labs, advanced equipment) and the need for technological expertise.

• (High) brand awareness, reputation for product quality, and innovation, allowing a player to compete against other competitive firms.

• (High) level of experience and a well-established global supply chain to achieve cost efficiency over new entrants who lack economies of scale.

Threat of Substitutes – Moderate to High

• (Moderate to high) alternative hearing solutions, including traditional hearing aids, bone-anchored hearing devices and emerging technologies in auditory solutions.

• (High) technological advancements in substitutes increase the appeal of non-implantable alternatives.

• (High) cost of cochlear implants makes more affordable hearing solutions attractive to individuals with hearing loss.

Bargaining Power of Suppliers – Moderate to High

• (Few) suppliers are qualified to provide specialised and high-quality components, including microelectronics, biocompatible materials, sound processors, batteries, and electrodes.

• (High) switching costs to move from one supplier to another due to lengthy vetting, qualification, and regulatory approvals (e.g. FDA in the U.S. and CE in Europe).

• (Moderate to high) risk of supply chain disruptions, such as raw material shortages, operational delays, or regulatory non-compliance.

Bargaining Power of Buyers – Moderate

• (Moderate to high) buyer power depending on specific buyer groups, such as hospitals, audiologists, individual patients, government healthcare programs and insurance providers.

• (High) switching costs for buyers of cochlear implants due to significant financial investment and time consumption, discouraging patients from changing brands.

• (Low) possibility for buyers to supply facilities and devices themselves because of the high technological complexity, specialised expertise and compliant regulatory standards.

Competitive Rivalry – High

• (Moderate to high) product differentiation, where each company distinguishes itself through features, technology, support services, and brand reputation.

• (High) fixed-cost industry, which may trigger price competition and constant pressure to invest substantially in R&D and innovation to retain customer loyalty and market shares.

• (Moderate to high) competitor balance due to a relative similarity in size, making each company compete intensively to defend its market position.

As highlighted by the five forces analysis, the medical device industry, particularly the hearing implant sector are considered profitable and attractive. The industry’s growth prospects are driven by increasing healthcare needs, aging populations, and technological advancements. However, the attractiveness is tempered by high barriers to entry (due to regulatory challenges and capital requirements), strong supplier power, and intense competition from both established players and potential substitutes.

For existing players like Cochlear, the industry remains attractive due to their ability to leverage established brand loyalty, economies of scale, and market leadership positioning. Conversely, for new entrants, these same forces present significant challenges that can hinder their market entry and long-term profitability.

Strategic groups

In the medical device industry, there are five groups of companies offering hearing solutions based on their scope of activities, market focus, and resource commitment.

• Full-Spectrum Hearing Solution Providers offer a wide range of hearing devices, from hearing aids to cochlear implants, addressing varying degrees of hearing loss. Strong global distribution networks, including retail and clinical channels. Some typical examples include Sonova (Phonak, Advanced Bionics) and Demant (Oticon, Oticon Medical).

• Cochlear Implant Specialists are dedicated primarily to cochlear implants and related advanced hearing solutions. Their product portfolio is narrower but deeply specialised. These companies include Cochlear, MED-EL and Advanced Bionics.

• Hearing Aid Market Leaders are companies that focus on traditional hearing aids, targeting mild to moderate hearing loss. They have extensive retail networks and direct-to-consumer channels. A few examples are Starkey, GN Hearing (ReSound) and WS Audiology (Widex, Signia).

• Consumer Technology Entrants enter the hearing solutions market with over-the-counter (OTC) or direct-to-consumer products. Their products are often classified as hearing enhancement rather than medical-grade solutions such as Bose and Apple (AirPods with hearing assistance features).

• Emerging Players and Innovators are startups and smaller companies that introduce novel technologies or target underserved markets. Their niche focus often caters to specific demographics or cost-sensitive markets. Some outstanding names are Eargo (discreet hearing aids) and Audientes (affordable solutions for developing countries).

Figure 1 indicates how these five groups were positioned in terms of breadth of product offering and market scope.

Figure 2 shows barriers confronting organisations that wished to move from one group to another. For instance, if the Cochlear implant specialists tried to enter the strategic group of Full-spectrum providers, they would need to invest significantly in R&D and develop expertise in non-invasive technologies, which differ from implantable solutions. Additionally, companies like Cochlear Limited or Med-EI are deeply associated with cochlear implants. Expanding into broader hearing solutions could dilute their brand or confuse customers.

Figure 3 shows where ‘strategic space’ might exist. These spaces are created by changes in the macro environment, especially consumer lifestyles and technological advancement. This could provide opportunities for the Cochlear implant specialists group to partner with tech companies to enhance and incorporate consumer-friendly features like app control, Bluetooth connectivity, and AI sound processing. Or they can consider acquiring those promising innovators to integrate new technology into their offerings. Although Cochlear implant specialists occupy a specialised niche market, given their established R&D infrastructures, competitive global distribution and key partnership networks, they can explore more comprehensive hearing solutions such as hybrid devices, which combine the benefits of both hearing aids and cochlear implants to attract customers in the overlapping market.

Key market segments

Cochlear Limited operates in the hearing implant market, with four key market segments:

It suggests that Cochlear has a strong position in developed markets among children but substantial opportunities for growth in:

• Emerging markets (both children and adults) due to low penetration rates.

• Adults and seniors in developed markets, where awareness is low but the potential market is large.

• The acoustic implant segment represents a new product category that could drive future growth in developed markets.

Diagnosing Strategic Capabilities

SWOT analysis

Using the SWOT framework, the following analysis identifies four key environmental factors that present both opportunities and threats:

• Shifts in Health Policy: Cochlear can benefit from policies supporting hearing health initiatives but may face challenges complying with rapidly changing regulations.

• Technological Advances: Continued innovation aligns with Cochlear’s R&D strengths.

• Healthcare Accessibility: Expanding global access to healthcare is a key opportunity for Cochlear, especially in underserved regions.

• Consumer Awareness: Increased awareness of hearing health among consumers creates growth potential.

The major strengths and weaknesses of Cochlear Limited have been identified as follows:

• Strengths

  • Market leader in implantable hearing solutions

  • Strong R&D and innovation focus

  • Established partnerships with medical institutions

• Weaknesses

  • High production costs

  • Limited presence in developing markets

  • Dependency on highly trained specialists

A scoring mechanism (plus 5 to minus 5) is used to assess the interrelationship between the environmental impacts and the strengths and weaknesses of the firm.

• A positive (+) denotes that the company’s strength would counteract, a problem arising from an environmental change.

• A negative (–) score denotes that a weakness would prevent the organisation from overcoming problems associated with that change.

When the above SWOT analysis examines the strengths, weaknesses, threats and opportunities of Cochlear Limited in relation to its direct competitors including Advanced Bionics and Med-EI, it showed that:

• Cochlear Limited was still outperforming its competitors in terms of innovation, partnerships, and strong branding but faced high R&D costs and compliance issues.

• Med-El shows strength in European markets but struggles with global adaptation and innovation compared to Cochlear.

• Advanced Bionics leverages AI-driven technology but lacks aggressive global marketing and affordability in developing markets.

Sustainable competitive advantage

At a threshold level, Cochlear Limited’s resources and capabilities effectively meet customer needs through high-quality cochlear implants and exceptional customer service. However, to achieve a sustainable competitive advantage, the following VIRO framework outlines the strategic capabilities that could differentiate the company and provide long-term advantage.

• Cochlear’s extensive research and development (R&D) capabilities and a skilful team behind are crucial assets, enabling them to consistently produce innovative hearing solutions. They are also an expert in meeting stringent regulatory approvals required for medical devices, which causes competitors to face substantial barriers if they attempt to replicate Cochlear’s advanced technological solutions, particularly in regions with strict healthcare regulations.

• The company also holds a strong patent portfolio and years of accumulated technological knowledge that makes imitation difficult. The time and financial resources required to establish similar expertise create further barriers to new entrants in this specialized industry.

• As one of the few companies dedicated solely to implantable hearing solutions, Cochlear’s significant market share in the cochlear implant segment, combined with its strong brand presence, provides a rare advantage that only a few competitors can match.

• Strong support from the organisational structure enables the company to leverage its global distribution networks and partnerships with healthcare professionals and clinics worldwide to streamline product delivery and ensure quality post-implantation service.

Benchmarking

If the SWOT and VRIO analyses in the preceding sections provide insights into Cochlear Limited’s key strategic capabilities, the benchmarking method can further enhance this understanding by comparing Cochlear’s internal processes and strategic capabilities with both its historical performance and those of other organizations in the industry. This allows Cochlear to assess how its strengths, operational efficiencies, and innovation practices measure up against its competitors, providing a clearer view of its competitive position and areas for improvement.

Historical benchmarking

Over the past 24 years, Cochlear has built a strong track record of strategic investment to drive growth, consistently delivering increasing sales revenue, profits*, and dividends. This success has been underpinned by the company’s ability to leverage its competitive advantages, including a trusted brand reputation, extensive global networks, and market leadership in cochlear implantable solutions.

Additionally, Cochlear’s growth strategy has been consistently demonstrated through its M&A activities since 1995, focusing on acquiring complementary technologies, expanding its product offerings, and enhancing operational efficiencies.

• In 1995, Cochlear entered a cooperation agreement with Siemens company in marketing, sales, distribution and R&D. 

• In 2000, Cochlear bought Philips Hearing Implants company. The deal has enabled the Group to launch the products faster into the market with the acquired technology and expertise. 

• In 2005, the entity bought Swedish-based Entific Medical Systems which enhanced the further growth in the respective cochlear implant market. 

• In 2006, Cochlear bought one of its key suppliers, Crystal Aid Manufacture Pty Ltd as part of the company’s supply chain redesign purpose. 

• In 2017, the company acquired Sycle LLC, the world’s largest provider of audiology office management software. 

• In 2022, Cochlear acquired a subsidiary of Danish multinational Demant, Oticon Medical which focuses on making hearing loss devices. 

Cochlear’s commitment to delivering technological advancements and product innovation lies at the core of its mission. Over 40 years of dedication to innovation have resulted in the development of some of the most advanced and reliable devices on the market.

Industry benchmarking

According to a report by IBISWorld in 2023, Cochlear significantly outperforms the industry average with the following:

• An EBITDA of A$470,400 compared to A$41,830. This demonstrates strong operational efficiency and profitability.

• A current ratio is 2.36, above the industry average of 2.22. This indicates better short-term liquidity and the ability to comfortably meet its current liabilities.

• A return on Shareholders’ Funds of 17.19%, exceeding the industry average of 15.7%. This highlights the company’s effective use of shareholders’ equity to generate profits.

• However, a lower asset turnover ratio compared to the industry average (0.76 vs. 0.81) suggests room for efficiency improvements in asset utilization. 

Cochlear also demonstrates superior performance in generating top-line growth with:

• An 18.06% revenue growth compared to the industry average of 10.74%.

• An asset growth of 4.2%, while the industry average shows a decline of -0.36%. This suggests that Cochlear is successfully expanding its asset base.

• An employee growth of 6.07%, in stark contrast to the industry average of -0.91%. This reflects an expanding workforce, likely driven by growth initiatives.

• Notably, a lagging in the NPAT growth area compared to the broader industry (3.97% vs 52.29%) mainly due to the impact of COVID-19 on the business with the deferral of cochlear implant surgeries across the world in the year 2020. 

Strategy Development

One-page strategic plan

Followed by an evaluation of Cochlear’s business environment and its strategic capabilities, a one-page strategic plan is laid out to provide a snapshot of how the organisation focuses its time and efforts on delivering value across the following initiatives:

• Grow the hearing implant market

• Retain market leadership

• Build a stronger organisation

• Minimise environmental impact

• Deliver sustained value

Performance summary

To ensure the effectiveness of the strategic plan, this section introduces a comprehensive framework for measuring Cochlear’s progress toward achieving its strategic vision. The table summarizing Cochlear’s FY24 performance highlights how the company aligned its four key perspectives—Market Leadership, Hearing Implant Market Growth, Organizational Development, and Environmental Sustainability—with measurable performance metrics, reinforcing its mission to improve lives through innovative hearing technologies:

• Market Leadership: Surpassed targets through product innovation, maintaining a market share of over 60%.

• Hearing Implant Market Growth: Achieved 9% unit growth while expanding in senior and emerging markets.

• Organizational Development: Progressed on track with 80% employee engagement, diversity milestones, and transformation initiatives.

• Environmental Sustainability: Exceeded goals by reducing emissions by 70% and utilizing 97% renewable energy in operations.

Recommendations

The brand strategy

Cochlear Limited was first established as an engineering company, which led to little surprise as to why it has paid so much attention to all product-related features, technology, and advancements. While this remains the unique differentiator of the entity to retain its market leadership based on product innovations, it is time for the organisation to consider building up a story around the emotional connection with the brand which is believed to result in better customer engagement. This can be achieved by:

• Create sub-brands that are strongly linked to the Cochlear Masterbrand with consistent logo elements, colour schemes, and design principles (e.g., “Cochlear Connect” for a youth-oriented app or “Cochlear Care” for a senior support program).

• Establish an Experiential Brand Hub, both physical and virtual space, to offer an immersive experience that demonstrates life with Cochlear’s solutions, access expert consultations and engage in workshops on hearing health.

New customer experience strategy

As it links to the new brand strategy proposal, Cochlear Limited should focus primarily on customer experience and engagement, instead of products compared to last time. As reported by the company’s executives, it can take a number of years for an individual with hearing loss to start a cochlear implant process due to a lack of knowledge, guidelines and referrals for hearing implants from doctors.

The enterprise could bring about positive outcomes by elevating customer experiences by implementing two main things. The first one is to embed the value of creating expanded customer benefits into the company’s mission and vision statement. This is one of the initial steps in changing the business mindset to put the customer at the heart of everything they do. The second phase is to redesign the customer experience journey starting with raising awareness of hearing impairment to understand the solutions, prepare for surgery, post-surgery lifetime support and services. That said to help customers go through the life cycle more satisfactorily aligning with the inner feeling of being heard and being well equipped with education and training.

Driving growth in the untapped market

According to Cochlear’s management report, approximately 360 million people worldwide are suffering from hearing loss. However, when factors such as household income, regulatory approvals, and insurance coverage are considered, the potential addressable market shrinks to 7 million individuals. Currently, Cochlear’s penetration within this market stands at around 7%.

Despite Cochlear’s leadership in the hearing implant segment, the company’s overall share within the broader hearing market remains relatively small. Hearing aids dominate the industry as the preferred solution, presenting a challenge for Cochlear to expand its market access and attract more patients without adjusting its current strategies.

As Cochlear’s CEO has acknowledged, achieving further growth in the hearing implant market requires innovation and diversification. Senior adults, a key demographic, may find hearing implants less appealing due to factors such as the lifespan of the product relative to their age, lifestyle changes or discomfort with surgical solutions or the cost associated with implants compared to alternatives like advanced hearing aids.

To overcome these barriers and drive growth, Cochlear can focus on diversifying its product and service pipeline. Key initiatives may include:

• Innovate second-best, non-surgical alternatives to implants that cater to aging populations

  Develop wearable, non-invasive hearing devices that combine advanced audio processing and artificial intelligence to offer a personalized hearing experience for those who may not be candidates for surgery due to age or health conditions.

• Offer high-quality, advanced solutions that bridge the gap between hearing aids and implants

  Develop hybrid devices that combine the benefits of both hearing aids and cochlear implants, allowing for a flexible solution that adapts to a patient’s needs over time.

• Continue collaborating with universities, research institutions, and healthcare providers to co-develop cutting-edge technologies

  Collaborate on the development of bioelectronic or neurostimulation technologies to provide hearing solutions that go beyond traditional implants and hearing aids, potentially improving long-term hearing recovery.

• Form strategic alliances with hearing aid manufacturers to integrate complementary products.

  Partner with leading hearing aid manufacturers to integrate cochlear implants with advanced hearing aids, creating a seamless solution that meets the diverse needs of patients with varying degrees of hearing loss.

• Identify and acquire firms with competitive technologies and strong footholds in underserved markets.

  Focus on expanding into developing markets by acquiring firms that have established distribution networks and strong local market knowledge, providing Cochlear with a faster route to market entry.

Conclusion

In summary, with the current financial performance, strategic plans, organisational structure and business objectives, Cochlear Group can still keep up with its global leadership in the cochlear implant market for some years. However, it will start seeing the obstacles along the way, especially when some of the key matured markets are saturated and the emerging market outcomes are hidden answers because of many variants comprising economic conditions, customer preferences and citizen affordability. These unforeseen situations require the management to flexibly develop contingent planning alongside its core strategies, which could be branding redesign, adding more value to customers such as re-creating customer experience mapping, or investing more in innovative alternative hearing solutions beyond the cochlear implants.

References

Anna, M 2021, How musical activities help speech perception, Cochlear, viewed 21/12/2023, <https://hearandnow.cochlear.com/hearing-solutions/services/improve-speech-perception-for-cochlear-implant/>.

Cochlear n.d., Cochlear CoPilot, Cochlear, viewed 21/12/2023, <https://www.cochlear.com/us/en/home/ongoing-care-and-support/rehabilitation-resources/copilot>.

Cochlear n.d., Nucleus® Implant reliability, Cochlear, viewed 21/12/2023, <https://www.cochlear.com/au/en/home/products-and-accessories/cochlear-nucleus-system/nucleus-implant-reliability>.

Cochlear n.d., Cochlear™ Provider Network, Cochlear, viewed 21/12/2023, <https://www.cochlear.com/us/en/professionals/cochlear-partnerships/cochlear-provider-network>.

Cochlear n.d., Personalized services and support, Cochlear, viewed 21/12/2023, <https://www.cochlear.com/us/en/home/ongoing-care-and-support/device-help-and-support/personalized-services-and-support>.

Cochlear n.d., Connecting people with hearing care, Cochlear, viewed 21/12/2023, <https://www.cochlear.com/us/en/professionals/connected-care/connecting-people-with-hearing-care>.

Cochlear 2022, New Professional Resources to Support Sound Processor Upgrades, Cochlear, viewed 21/12/2023, <https://pronews.cochlear.com/new-professional-resources-to-support-sound-processor-upgrades/>.

Cochlear n.d., Training Support, Cochlear, viewed 21/12/2023, <https://www.cochlear.com/au/en/professionals/training-and-development/training-support>.

Cochlear Limited 2023, Annual Report 2023, Cochlear Limited, viewed 21/11/2023, <chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://assets.cochlear.com/api/public/content/db4f441469aa4263acccdfc23980d21b?v=ce8bbd15>.

Cochlear Limited 2020, Strategy Overview 2020, Cochlear Limited, viewed 21/11/2023, <chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://assets.cochlear.com/api/public/content/9ef766f2a6a045c3890099428077c267?v=62087d53>.

Department of Head and Neck Surgery and Communication Sciences 2023, Forbes Health: How Much Do Cochlear Implants Cost?, Duke University School of Medicine, viewed 22/12/2023, <https://headnecksurgery.duke.edu/news/forbes-health-how-much-do-cochlear-implants-cost>.

Eli, G 2005, Cochlear expands reach with Entific buy, Financial Review, viewed 22/12/2023, <https://www.afr.com/companies/cochlear-expands-reach-with-entific-buy-20050305-jl67s>.

Fern Fort University n.d., Cochlear Limited PESTEL & Environment Analysis, Fern Fort University, viewed 21/12/2023, <http://fernfortuniversity.com/term-papers/pestel/nyse4/4888-cochlear-limited.php>.

James, C 2021, Organic Growth: What It Is, and Why It Matters to Investors, Investopedia, viewed 22/12/2023, <https://www.investopedia.com/terms/o/organicgrowth.asp>.

Jay, J 2023, The Role Of M&A In Growth Strategy, Linkedin, viewed 22/12/2023, <https://www.linkedin.com/pulse/role-ma-growth-strategy-jay-jung/>.

Intrafocus 2016, Balanced Scorecard Example, Intrafocus, viewed 22/12/2023, <https://www.intrafocus.com/2016/06/balanced-scorecard-example/>.

IBIS World 2023, Australia Company Profiles: Cochlear Limited, IBIS World, viewed 20/11/2023, < https://my.ibisworld.com/au/en/company-reports/6207/company-details>.

Grand View Research n.d., Cochlear Implant Market Size & Share Report, 2030, Grand View Research, viewed 22/12/2023, <https://www.grandviewresearch.com/industry-analysis/cochlear-implants-industry>.

Graham, W 2018, The truth about Cochlear’s market share, Intelligent Investor, viewed 20/11/2023, <https://www.intelligentinvestor.com.au/recommendations/the-truth-about-cochlears-market-share/142882>.

MedTech Insight 2000, Cochlear buys Philips Hearing Implants, MedTech, viewed 22/12/2023, <https://medtech.citeline.com/MT076042/Cochlear-buys-Philips-Hearing-Implants>.

Morning Star n.d., Cochlear Ltd, Morning Star, viewed 21/11/2023, <https://www.morningstar.com.au/investments/security/ASX/COH>.

Nadia, C 2015, How Cochlear is tuning into customer lifecycle marketing, CMO, viewed 23/12/2023, <https://www.cmo.com.au/article/584582/how-cochlear-tuning-into-customer-lifecycle-marketing/>.

Nadube, P.M. and Didia, J.U.D., 2018. Market targeting and strategic positioning. International Journal of Marketing Research and Management, 8(1), pp.32-45, <chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.researchgate.net/profile/Paul-Nadube-2/publication/336773986_Market_targeting_and_strategic_positioning/links/5db1964692851c577eba7d24/Market-targeting-and-strategic-positioning.pdf>.

Rosalyn, P 2023, Why the time was right for Cochlear’s brand transformation, CMO, viewed 23/12/2023,< https://www.cmo.com.au/article/704111/why-time-right-cochlear-brand-transformation/>.

Simply Wall St n.d., Cochlear Limited Company Information, Simply Wall St, viewed 21/12/2023, <https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/information>.

The Sydney Morning Herald 2006, Cochlear buys key supplier for $19m, The Sydney Morning Herald, viewed 22/12/2023, <https://www.smh.com.au/business/cochlear-buys-key-supplier-for-19m-20061219-gdp2zr.html>.

The Hearing Review 2017, Cochlear Ltd Purchases Sycle, The Hearing Review, viewed 22/12/2023, <https://hearingreview.com/practice-building/office-services/cochlear-ltd-purchases-sycle>.

Yolanda, R 2022, Cochlear acquires unit of Danish rival for $170m, Financial Review, viewed 22/12/2023, <https://www.afr.com/companies/healthcare-and-fitness/cochlear-acquires-unit-of-danish-rival-for-170m-20220427-p5agnc>.